Episode 145: GU Podcast (2020): Targeted Therapies and Integration with Surgical Management of RCC

At the conclusion of this activity, participants will be able to:
1. Describe new and emerging targeted for patients with locally-advanced and advanced kidney cancer and the role of adjuvant therapy.
2. Review the mechanisms of action, efficacy, and safety of currently available targeted treatment of RCC.
3. Facilitate discussions with patients and caregivers regarding RCC treatment options.

This educational series is supported by independent educational grants from:

• Astellas
• AstraZeneca
• Bristol Myers Squibb
• Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
• Merck
• Pfizer, Inc
• Sanofi Genzyme
• UroGen Pharma, Inc.

CME Available: auau.auanet.org/node/29851